PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34893156-7 2021 The polymorphism rs1695 of the GSTP1 gene has been associated with the effectiveness and toxicity of fluorouracil, cyclophosphamide and epirubicin therapy. Fluorouracil 101-113 glutathione S-transferase pi 1 Homo sapiens 31-36 21468552-7 2011 A similar reaction has also been observed in patients with the XRCC1 Arg399Gln polymorphism, while patients with the GSTP1 Ile105Val polymorphism have an improved response to oxaliplatin/5FU therapy. Fluorouracil 187-190 glutathione S-transferase pi 1 Homo sapiens 117-122 25677905-1 2015 The most important cytotoxic drug namely, cyclophosphamide used in breast cancer along with epirubicin and 5-fluorouracil, is transported by ABCC transporters and detoxified by glutathione S-transferases (GSTs). Fluorouracil 107-121 glutathione S-transferase pi 1 Homo sapiens 205-209 23842854-10 2013 In conclusion, the GSTP1 expression is a good predictor of prognosis, and it may be closely related to the chemotherapeutic efficacy of 5-FU plus cisplatin in ESCC patients. Fluorouracil 136-140 glutathione S-transferase pi 1 Homo sapiens 19-24 24137384-11 2013 GSTP1-105 and GSTM1 genotypes may be useful markers of severe peripheral neuropathy in MCRC patients treated with 5-FU/oxaliplatin as first-line chemotherapy. Fluorouracil 114-118 glutathione S-transferase pi 1 Homo sapiens 0-5 31019568-0 2019 Overexpression of long noncoding RNA LINC01419 in esophageal squamous cell carcinoma and its relation to the sensitivity to 5-fluorouracil by mediating GSTP1 methylation. Fluorouracil 124-138 glutathione S-transferase pi 1 Homo sapiens 152-157 31019568-2 2019 Herein, this study elucidates the role and mechanism by which LINC01419 regulates the DNA methylation of glutathione S-transferase pi 1 (GSTP1) in relation to ESCC progression and the sensitivity of ESCC cells to 5-fluorouracil (5-FU). Fluorouracil 213-227 glutathione S-transferase pi 1 Homo sapiens 105-135 31019568-2 2019 Herein, this study elucidates the role and mechanism by which LINC01419 regulates the DNA methylation of glutathione S-transferase pi 1 (GSTP1) in relation to ESCC progression and the sensitivity of ESCC cells to 5-fluorouracil (5-FU). Fluorouracil 213-227 glutathione S-transferase pi 1 Homo sapiens 137-142 31019568-2 2019 Herein, this study elucidates the role and mechanism by which LINC01419 regulates the DNA methylation of glutathione S-transferase pi 1 (GSTP1) in relation to ESCC progression and the sensitivity of ESCC cells to 5-fluorouracil (5-FU). Fluorouracil 229-233 glutathione S-transferase pi 1 Homo sapiens 105-135 31019568-2 2019 Herein, this study elucidates the role and mechanism by which LINC01419 regulates the DNA methylation of glutathione S-transferase pi 1 (GSTP1) in relation to ESCC progression and the sensitivity of ESCC cells to 5-fluorouracil (5-FU). Fluorouracil 229-233 glutathione S-transferase pi 1 Homo sapiens 137-142 31019568-7 2019 Notably, LINC01419 could bind to the promoter region of the GSTP1 gene, resulting in elevated GSTP1 methylation and reduced GSTP1 levels via the recruitment of DNA methyltransferase among ESCC cells, whereby ESCC progression was stimulated accompanied by reduced ESCC cell sensitivity to 5-FU. Fluorouracil 288-292 glutathione S-transferase pi 1 Homo sapiens 60-65 31019568-8 2019 GSTP1 demethylation by 5-Aza-CdR was observed to reverse the effects of LINC01419 overexpression in ESCC cells and the response to 5-FU. Fluorouracil 131-135 glutathione S-transferase pi 1 Homo sapiens 0-5 31019568-9 2019 Conclusion: Highly expressed LINC01419 in ESCC promotes GSTP1 methylation, which ultimately acts to promote the event of ESCC and diminish the sensitivity of ESCC cells to 5-FU, highlighting a novel potential strategy to improve 5-FU-based chemotherapy in ESCC. Fluorouracil 172-176 glutathione S-transferase pi 1 Homo sapiens 56-61 31019568-9 2019 Conclusion: Highly expressed LINC01419 in ESCC promotes GSTP1 methylation, which ultimately acts to promote the event of ESCC and diminish the sensitivity of ESCC cells to 5-FU, highlighting a novel potential strategy to improve 5-FU-based chemotherapy in ESCC. Fluorouracil 229-233 glutathione S-transferase pi 1 Homo sapiens 56-61 24970398-11 2014 Finally, knockdown of GSTP-1 promoted the sensitivity of SNU-407 cells to the anticancer agent 5-fluorouracil. Fluorouracil 95-109 glutathione S-transferase pi 1 Homo sapiens 22-28 22320227-1 2012 The purpose of the present study was to investigate the association of glutathione S-transferase P1 (GSTP1) expression with resistance to neoadjuvant paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (P-FEC) in human breast cancers. Fluorouracil 173-187 glutathione S-transferase pi 1 Homo sapiens 71-99 21940361-0 2012 Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Fluorouracil 55-69 glutathione S-transferase pi 1 Homo sapiens 45-50 21940361-9 2012 CONCLUSIONS: Immunohistochemical studies for ERCC-1 and GST-p may be useful in prediction of the response to 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer patients. Fluorouracil 109-123 glutathione S-transferase pi 1 Homo sapiens 56-61 21029695-0 2010 [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy]. Fluorouracil 140-144 glutathione S-transferase pi 1 Homo sapiens 60-65 21133646-0 2011 Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Fluorouracil 162-166 glutathione S-transferase pi 1 Homo sapiens 66-94 21133646-1 2011 The objective of this study was to determine whether the expressions of the excision cross-complementing (ERCC1), thymidylate synthase (TS) and glutathione S-transferase P1 (GSTP1) are predictive of clinical outcomes in advanced gastric cancer (AGC) patients receiving treatment with adjuvant 5-fluorouracil (5-FU) and cisplatin (FP) chemotherapy. Fluorouracil 293-307 glutathione S-transferase pi 1 Homo sapiens 174-179 21133646-1 2011 The objective of this study was to determine whether the expressions of the excision cross-complementing (ERCC1), thymidylate synthase (TS) and glutathione S-transferase P1 (GSTP1) are predictive of clinical outcomes in advanced gastric cancer (AGC) patients receiving treatment with adjuvant 5-fluorouracil (5-FU) and cisplatin (FP) chemotherapy. Fluorouracil 309-313 glutathione S-transferase pi 1 Homo sapiens 174-179 21029695-10 2010 CONCLUSION: Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with TTP and OS of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based combination chemotherapy as the first-line chemotherapy. Fluorouracil 164-168 glutathione S-transferase pi 1 Homo sapiens 62-67 17322540-0 2007 Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Fluorouracil 100-114 glutathione S-transferase pi 1 Homo sapiens 67-95 20514304-0 2010 Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Fluorouracil 77-81 glutathione S-transferase pi 1 Homo sapiens 24-29 20514304-1 2010 The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Fluorouracil 143-147 glutathione S-transferase pi 1 Homo sapiens 79-107 20514304-1 2010 The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Fluorouracil 143-147 glutathione S-transferase pi 1 Homo sapiens 109-114 20047135-0 2009 Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Fluorouracil 54-58 glutathione S-transferase pi 1 Homo sapiens 25-30 20047135-8 2009 CONCLUSION: The GSTP1 105Val/105Val genotype is associated with a higher clinical response rate to oxaliplatin-based chemotherapy and with increased survival of patients with advanced colo-rectal cancer, receiving 5-FU/oxaliplatin chemotherapy. Fluorouracil 214-218 glutathione S-transferase pi 1 Homo sapiens 16-21 17551301-7 2007 For stage II/III patients, to have 2 or 3 polymorphisms of 3R/3R of 5"-TSER, a 6 bp of 3"-TSUTR, and GSTP1-Ile105Val resulted in an extensively longer survival (P = 0.020), although no difference was found between 2 groups, with respect to the plasma concentrations of 5-FU and clinicopathologic characteristics. Fluorouracil 269-273 glutathione S-transferase pi 1 Homo sapiens 101-106 17322540-1 2007 BACKGROUND: The aim of this study was to determine whether expressions of the excision repair cross-complementing (ERCC1), thymidylate synthase (TS), and glutathione S-transferase P1 (GSTP1) predict clinical outcome in patients with advanced gastric cancer treated with fluorouracil (5-fluorouracil)/oxaliplatin chemotherapy. Fluorouracil 284-298 glutathione S-transferase pi 1 Homo sapiens 184-189 17322540-1 2007 BACKGROUND: The aim of this study was to determine whether expressions of the excision repair cross-complementing (ERCC1), thymidylate synthase (TS), and glutathione S-transferase P1 (GSTP1) predict clinical outcome in patients with advanced gastric cancer treated with fluorouracil (5-fluorouracil)/oxaliplatin chemotherapy. Fluorouracil 270-282 glutathione S-transferase pi 1 Homo sapiens 184-189 17265526-10 2007 CONCLUSIONS: The GSTP1*C variant conferred a possible protective effect against pancreatic cancer in older individuals and a significant survival advantage in patients who received 5-florouracil. Fluorouracil 181-194 glutathione S-transferase pi 1 Homo sapiens 17-22 16317430-11 2006 Testing for TS and GSTP1 polymorphisms may allow identification of gastric cancer patients who will benefit from 5-FU/cisplatin chemotherapy, sparing others the side effects of this chemotherapy. Fluorouracil 113-117 glutathione S-transferase pi 1 Homo sapiens 19-24 15213713-2 2004 Functional polymorphisms in DNA-repair genes XPD, ERCC1, XRCC1, XPA, and metabolising genes glutathione S-transferase GSTP1, GSTT1, GSTM1, and thymidylate synthase (TS) were assessed retrospectively in 106 patients with refractory stage IV disease who received 5-FU/oxaliplatin combination chemotherapy, using a polymerase chain reaction-based RFLP technique. Fluorouracil 261-265 glutathione S-transferase pi 1 Homo sapiens 118-123 12072547-4 2002 In a retrospective study, we investigated associations between common polymorphisms in genes for several GST subclasses (GSTP1, GSTT1, GSTM1) and survival of patients with metastatic colorectal cancer receiving 5-fluorouracil (5-FU)/oxaliplatin chemotherapy. Fluorouracil 211-225 glutathione S-transferase pi 1 Homo sapiens 121-126 12072547-13 2002 CONCLUSIONS: The GSTP1 Ile(105)Val polymorphism is associated in a dose-dependent fashion with increased survival of patients with advanced colorectal cancer receiving 5-FU/oxaliplatin chemotherapy. Fluorouracil 168-172 glutathione S-transferase pi 1 Homo sapiens 17-22